Egetis Therapeutics Awaits FDA Decision on Emcitate for MCT8 Deficiency

Egetis Therapeutics approaches a U.S. regulatory milestone as it awaits an FDA decision on its lead drug candidate, Emcitate (tiratricol), for the treatment of MCT8 deficiency. The agency set a Prescription Drug User Fee Act (PDUFA) target action date of September 28, 2026.

The company secured regulatory clearance in other markets, yet the U.S. remains a key market. Emcitate received European Commission approval in February 2025, but it is currently not approved for commercial sale in the United States.

"Egetis has been ‘flying under the radar,’ especially among U.S. investors," said Nicklas Westerholm, CEO of Egetis Therapeutics, during a recent presentation at the Cantor healthcare conference.

Expanded Access and Patient Reach

Ahead of the potential U.S. launch, the company provided the treatment to patients with the rare disease through an expanded access program. Company data indicates that 60 patients are currently enrolled in the U.S. expanded access program for Emcitate.

MCT8 deficiency is a rare, X-linked genetic disorder characterized by severe developmental delay and neurological impairment. Because the condition affects a limited patient population, the regulatory path for orphan drugs like Emcitate often involves smaller clinical trial cohorts. This makes the upcoming PDUFA date an indicator for the company's revenue potential.

Commercial Strategy and Market Positioning

The September 28 deadline represents the result of efforts by Egetis to expand its geographic reach. By securing FDA approval, the company aims to transition from a European-focused entity to a global participant in the rare disease market. The management team is using investor conferences to increase visibility among U.S.-based institutional and retail investors, seeking to address the status noted by Westerholm.

The outcome of the FDA review will determine whether the company can begin building a commercial infrastructure in the U.S. to support the launch of Emcitate, which remains the centerpiece of its therapeutic pipeline.